| scholarly article | Q13442814 |
| P356 | DOI | 10.1677/ERC-09-0101 |
| P698 | PubMed publication ID | 19620247 |
| P50 | author | Márta Korbonits | Q48888114 |
| Ashley Grossman | Q112494568 | ||
| P2093 | author name string | M Teng | |
| M Cakir | |||
| B Kola | |||
| M Korbonits | |||
| N Prodromou | |||
| M Gueorguiev | |||
| D Dworakowska | |||
| S Grozinsky-Glasberg | |||
| C A Leontiou | |||
| E Wlodek | |||
| M I Góth | |||
| S Igreja | |||
| P433 | issue | 4 | |
| P304 | page(s) | 1329-1338 | |
| P577 | publication date | 2009-07-20 | |
| P1433 | published in | Endocrine-Related Cancer | Q3054004 |
| P1476 | title | Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. | |
| P478 | volume | 16 |
| Q42580149 | AMPK activity is down-regulated in endothelial cells of GHS-R(-/-) mice. |
| Q38709661 | Aryl hydrocarbon receptor (AHR) is a potential tumour suppressor in pituitary adenomas |
| Q41757805 | CMTM3 inhibits cell growth and migration and predicts favorable survival in oral squamous cell carcinoma |
| Q34729384 | Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families |
| Q33685337 | Chemokine-like factor-like MARVEL transmembrane domain-containing 3 expression is associated with a favorable prognosis in esophageal squamous cell carcinoma |
| Q97419894 | Contemporary Management of Clinically Non-functioning Pituitary Adenomas: A Clinical Review |
| Q64376260 | Dysregulation of Krüppel-like factor 12 in the development of endometrial cancer |
| Q36850160 | Each individual isoform of the dopamine D2 receptor protects from lactotroph hyperplasia |
| Q90679554 | Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting |
| Q90360237 | Effects of Oxytocin on Cell Proliferation in a Corticotroph Adenoma Cell Line |
| Q39381450 | Effects of STAT3 gene silencing and rapamycin on apoptosis in hepatocarcinoma cells |
| Q38284921 | Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System. |
| Q38176659 | Emerging drugs for acromegaly |
| Q89510579 | Exploring the Role of Novel Medical Therapies for Aggressive Pituitary Tumors: A Review of the Literature-"Are We There Yet?" |
| Q57584839 | Expression and Clinical Significance of Wnt Players and Survivin in Pituitary Tumours |
| Q33984418 | Genetically engineered mouse models of pituitary tumors |
| Q37706227 | Genome-wide analysis of differentially expressed lncRNAs and mRNAs in primary gonadotrophin adenomas by RNA-seq |
| Q38502919 | Genome-wide screening of indicator genes for assessing the potential carcinogenic risk of Nanjing city drinking water |
| Q38397298 | HGF/c-met system targeting PI3K/AKT and STAT3/phosphorylated-STAT3 pathways in pituitary adenomas: an immunohistochemical characterization in view of targeted therapies. |
| Q36579434 | Heme oxygenase-1 attenuates IL-1β induced alteration of anabolic and catabolic activities in intervertebral disc degeneration |
| Q36291593 | In1-ghrelin splicing variant is overexpressed in pituitary adenomas and increases their aggressive features. |
| Q39387231 | Insulin-like growth factor binding protein 7 modulates estrogen-induced trophoblast proliferation and invasion in HTR-8 and JEG-3 cells |
| Q92529952 | Lineage-dependent role of miR-410-3p as oncomiR in gonadotroph and corticotroph pituitary adenomas or tumor suppressor miR in somatotroph adenomas via MAPK, PTEN/AKT, and STAT3 signaling pathways |
| Q38784816 | MAPK pathway control of stem cell proliferation and differentiation in the embryonic pituitary provides insights into the pathogenesis of papillary craniopharyngioma. |
| Q34148960 | MicroRNA profile indicates downregulation of the TGFβ pathway in sporadic non-functioning pituitary adenomas |
| Q38165863 | Molecular basis of pharmacological therapy in Cushing's disease |
| Q92537519 | Multiomics-Based Signaling Pathway Network Alterations in Human Non-functional Pituitary Adenomas |
| Q47329769 | Nelfinavir induces radiation sensitization in pituitary adenoma cells. |
| Q39715502 | New targeted therapies in pituitary carcinoma resistant to temozolomide |
| Q38007118 | PI3K/Akt/mTOR and Raf/MEK/ERK signaling pathways perturbations in non-functioning pituitary adenomas |
| Q47698409 | PI3K/Akt/mTOR pathway involvement in regulating growth hormone secretion in a rat pituitary adenoma cell line. |
| Q47710841 | PSCA promotes prostate cancer proliferation and cell-cycle progression by up-regulating c-Myc. |
| Q83667492 | Pathogenesis of pituitary tumors |
| Q34603037 | Persistent ERK/MAPK activation promotes lactotrope differentiation and diminishes tumorigenic phenotype |
| Q37851164 | Physiopathology of somatolactotroph cells: from transduction mechanisms to cotargeting therapy. |
| Q26781442 | Pituitary Adenoma and the Chemokine Network: A Systemic View |
| Q54961209 | Pituitary-Directed Therapies for Cushing's Disease. |
| Q41354217 | Retinoblastoma protein (Rb) links hypoxia to altered mechanical properties in cancer cells as measured by an optical tweezer |
| Q38947158 | Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells. |
| Q43465192 | Signal transduction disturbance related to hepatocarcinogenesis in mouse by prolonged exposure to Nanjing drinking water |
| Q48216956 | Significant response of pituitary carcinoma to carboplatin, leucovorin and fluorouracil chemotherapy: a pediatric case report and review of the literature. |
| Q37564373 | Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives |
| Q33753449 | Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. |
| Q39293265 | Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-γ-related pathways |
| Q38107011 | Targeted therapy with kinase inhibitors in aggressive endocrine tumors |
| Q42317496 | Targeting the ERK pathway for the treatment of Cushing's disease |
| Q64996748 | The MAPK Pathway-Based Drug Therapeutic Targets in Pituitary Adenomas. |
| Q55144847 | The Molecular Pathology of Cushing Disease: Are We Nearly There? |
| Q26770404 | The PI3K/Akt Pathway in Tumors of Endocrine Tissues |
| Q92699881 | The Treatment of Refractory Pituitary Adenomas |
| Q37958029 | The molecular pathogenesis of corticotroph tumours |
| Q37760900 | The potential role of mTOR inhibitors in the treatment of endocrine tumors |
| Q30872897 | Treatment of pituitary carcinomas and atypical pituitary adenomas: a review |
| Q48519733 | Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy |
| Q44536883 | mTOR is frequently active in GH-secreting pituitary adenomas without influencing their morphopathological features. |
| Q51571729 | mTOR promotes pituitary tumor development through activation of PTTG1. |
Search more.